IC51 Japanese encephalitis vaccine

Expert Opinion on Biological Therapy

Volumn 9, Issue 7, 2009, Pages 921-931

  Kollaritsch, Herwig ^a   Paulke Korinek, Maria ^a   Dubischar Kastner, Katrin ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INTERCELL AG   (Austria)

Author keywords

IC51; Immunization; IXIARO; Japanese encephalitis virus; JESPECT; Vaccination; Vaccine

Indexed keywords

ALPHA2A INTERFERON; HEPATITIS A VACCINE; INACTIVATED VIRUS VACCINE; IXIARO; JAPANESE ENCEPHALITIS VACCINE; JESPECT; LIVE VACCINE; PLACEBO; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ACUTE DISEASE; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; AUSTRALIA; BRONCHITIS; CELL CULTURE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENCEPHALOMYELITIS; ENDEMIC DISEASE; EPIDEMIC ENCEPHALITIS; EUROPE; FEVER; FLAVIVIRUS; FLU LIKE SYNDROME; HAMSTER; HUMAN; IMMUNOGENICITY; INFECTION RISK; JAPANESE ENCEPHALITIS VIRUS; KIDNEY CELL; MORTALITY; MYALGIA; NEUROLOGIC DISEASE; NONHUMAN; POPULATION; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SINUSITIS; SPRING; UNITED STATES; URINARY TRACT INFECTION; URTICARIA;

ANIMALS; CLINICAL TRIALS AS TOPIC; CRICETINAE; ENCEPHALITIS, JAPANESE; HUMANS; JAPANESE ENCEPHALITIS VACCINES; MICE;

FLAVIVIRUS; JAPANESE ENCEPHALITIS VIRUS;

EID: 67650366791     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903042282     Document Type: Review

References (70)

1. Thiel H-J, Collett MS, Gould EA, et al. Index of Viruses - Flaviviridae ICTVdB - The Universal Virus Database, version 4: Büchen-Osmond C, Editor, Columbia University, New York, USA 2006. Available from: http://www.ncbi.nlm. nih.gov/ICTVdb/Ictv/fs-index.htm [Last accessed 26 May 2009]
2. Solomon T, Ni H, Beasley DWC, et al. Origin and evolution of Japanese encephalitis virus in southeast Asia. J Virol 2003;77(5):3091-3098 (Pubitemid 36228095)
3. Sumiyoshi H, Mori C, Fuke I, et al. Complete nucleotide sequence of the Japanese encephalitis virus genome RNA. Virology 1987;161(2):497-510
4. Ma SP, Yoshida Y, Makino Y, et al. Short report: A major genotype of Japanese encephalitis virus currently circulating in Japan. Am J Trop Med Hyg 2003;69(2):151-154
5. Oya A, Kurane I. Japanese encephalitis for a reference to international travelers. J Travel Med 2007;14(4):259-268 (Pubitemid 47041480)
6. Konishi E, Yamaoka M, Khin Sane W, et al. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. J Virol 1999;73(7):5527-5534 (Pubitemid 29274836)
7. Beasley DW, Li L, Suderman MT, et al. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine 2004;22(27-28):3722-3726 (Pubitemid 39099648)
8. Chiou SS, Tsai KH, Huang CG, et al. High antibody prevalence in an unconventional ecosystem is related to circulation of a low-virulent strain of Japanese encephalitis virus. Vaccine 2007;25(8):1437-1443 (Pubitemid 46074298)
9. Halstead SB, Jacobson J. Japanese Encephalitis Vaccines. In: Plotkin SA, Orenstein WA, Offit P, editors, Vaccines. Fourth edition: Philadelphia: Saunders Elsevier, 2008 •A comprehensive review of Japanese Encephalitis as a vaccine-preventable disease and available vaccines.
10. Sunish IP, Reuben R. Factors influencing the abundance of Japanese encephalitis vectors in ricefields in India - I. Abiotic. Med Vet Entomol 2001;15(4):381-392 (Pubitemid 34025621)
11. Centers for Disease Control and Prevention. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1993;42(RR-1):1-15
12. Gould DJ, Byrne RJ, Hayes DE. Experimental infection of horses with Japanese encephalitis virus by mosquito bite. Am J Trop Med Hyg 1964;13(5):742-746
13. Japanese Encephalitis vaccines: WHO position paper. Wkly Epidemiol Rec 2006;81:331-340
14. WHO. Japanese encephalitis. Available from: http://www.who.int/vaccine- research/diseases/vector/en/index1.html [Last accessed 26 May 2009]
15. Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: Minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 2000;18(Suppl 2):1-25 (Pubitemid 30251998)
16. Hanna J, Ritchie S, Phillips D, et al. Japanese encephalitis in north Queensland, Australia, 1998. Med J Aust 1999;170(11):533-536 (Pubitemid 28102711)
17. Beasley DW, Lewthwaite P, Solomon T. Current use and development of vaccines for Japanese encephalitis. Expert Opin Biol Ther 2008;8(1):95-106 (Pubitemid 351233725)
18. SEARO WHO. Immunization and Vaccine Development, Japanese Encephalitis. 2005; Available from: http://www.searo.who.int/en/section1226/section2073.asp [Last accessed 26 May 2009]
19. Solomon T. Control of Japanese encephalitis - within our grasp? N Engl J Med 2006;355(9):869-871
20. WHO. Report of the Bi-Regional Meeting on Japanese Encephalitis, 2005. Available from: http://www.wpro.who.int/NR/rdonlyres/A62D4A75-0C28-4093-95CF- 555CE379C469/0/MTGRPT-BiregionalJE2005.pdf [Last accessed 26 May 2009]
21. Gajanana A, Thenmozhi V, Samuel PP, Reuben R. A community-based study of subclinical flavivirus infections in children in an area of Tamil Nadu, India, where Japanese encephalitis is endemic. Bull World Health Organ 1995;73(2):237-244
22. Steinhoff MC. Japanese encephalitis: a Chinese solution? Lancet 1996;347(9015):1570-1571
23. Gould EA, Solomon T. Pathogenic flaviviruses. Lancet 2008;371(9611):500- 509
24. Solomon T, Dung NM, Wills B, et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet 2003;361(9360):821-826 (Pubitemid 36331845)
25. Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007;370(9602):1847-1853 •• A pivotal PhaseIII immunogenicity study of IXIARO.
26. Oya A. Japanese encephalitis vaccine. Acta Paediatr Jpn 1988;30(2):175-184
27. Schioler KL, Samuel M, Wai KL. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst Rev 2007;3:1-44
28. Jelinek T. Japanese encephalitis vaccine in travelers. Expert Rev Vaccines 2008;7(5):689-693
29. Sugawara K, Nishiyama K, Ishikawa Y, et al. Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 2002;30(4):303-314 (Pubitemid 36268966)
30. Sakaguchi M, Miyazawa H, Inouye S. Specific IgE and IgG to gelatin in children with systemic cutaneous reactions to Japanese encephalitis vaccines. Allergy 2001;56(6):536-539 (Pubitemid 32521435)
31. Hanna JN, Smith GA, Mcculloch BG, et al. An assessment of the interval between booster doses of Japanese encephalitis vaccine in the Torres Strait. Aust N Z J Public Health 2005;29(1):44-47 (Pubitemid 40378671)
32. Abe M, Okada K, Hayashida K, et al. Duration of neutralizing antibody titer after Japanese encephalitis vaccination. Microbiol Immunol 2007;51(6):609-616 (Pubitemid 46974978)
33. Kollaritsch H. Japan-B-Encephalitis. In: Kollaritsch H, Wiedermann G, editors, Leitfaden für Schutzimpfungen. Wien: Springer Verlag, 2000
34. Xin YY, Ming ZG, Peng GY, etal. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am J Trop Med Hyg 1988;39(2):214-217 (Pubitemid 18222495)
35. Eckels KH, Yu YX, Dubois DR, et al. Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine 1988;6(6):513-518
36. WHO. Global Advisory Committee on Vaccine Safety, 9-10 June 2005. Wkly Epidemiol Rec 2005;28(80):242-243
37. Yaïch M, Jacobson J. Satellite symposium on Japanese encephalitis and dengue vaccine research. Proceedings of the seventh global vaccine research forum and parallel satellite symposia, 3-6 December 2006, 2007. Available from: http://whqlibdoc.who.int/hq/2007/WHO-IVB-07.10-eng.pdf [Last accessed 26 May 2009]
38. Liu ZL, Hennessy S, Strom BL, et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J Infect Dis 1997;176(5):1366-1369 (Pubitemid 27461005)
39. Hennessy S, Liu Z, Tsai TF, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 1996;347(9015):1583-1586 (Pubitemid 26170875)
40. Tandan JB, Ohrr H, Sohn YM, etal. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case-control study in Nepalese children 5years after immunization. Vaccine 2007;25(27):5041-5045
41. Gatchalian S, Yao Y, Zhou B, et al. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine 2008;26(18):2234-2241
42. Applied Strategies. GAVI Vaccine Investment Strategy. Landscape Analysis - Japanese Encephalitis 2008. Available from: http://www.gavialliance.org/ resources/18-JE-Landscape-Jun08.pdf [Last accessed 26 May 2009]
43. Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003;188(8):1213-1230 (Pubitemid 37338987)
44. Solomon T. New vaccines for Japanese encephalitis. Lancet Neurol 2008;7(2):116-118
45. Lyons A, Kanesa-Thasan N, Kuschner RA, etal. A Phase2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 2007;25(17):3445-3453 •• PhaseII clinical data for IXIARO.
46. Srivastava AK, Putnak JR, Lee SH, et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 2001;19(31):4557-4565 (Pubitemid 32718682)
47. Available from: http://clinicaltrials.gov/ct2/results?term=IC51
48. Hombach J, Solomon T, Kurane I, et al. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005;23(45):5205-5211 • Discussion of the suitability of neutralizing antibodies as immunological endpoints in trials of JE vaccines.
49. Schuller E, Klade CS, Wolfl G, et al. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: A randomized, observer-blind, controlled Phase3 study. Vaccine 2009;27(15):2188-2193 • This paper describes the immune response kinetics of IXIARO, demonstrating protection 7 days after the second dose.
50. Schuller E, Jilma B, Voicu V, et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 2008;26(34):4382-4386 • This paper describes long-term immunogenicity results for IXIARO, demonstrating protective titers in over 80% of vaccinees after one year.
51. Schuller E, Klade CS, Heinz FX, et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 2008;26(48):6151-6156 •• Evidence is presented that TBE pre-immune subjects mount a higher immune response to the first dose of IXIARO.
52. Hoke CH, Nisalak A, Sangawhipa N, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1988;319(10):608-614 • A field efficacy trial of JE-VAX in Thailand.
53. Hammon WM, Sather GE. Passive immunity for arbovirus infection. I. Artificially induced prophylaxis in man and mouse for Japanese (B) encephalitis. Am J Trop Med Hyg 1973;22(4):524-534
54. Intercell. Intercell for Vaccperts. Available from: http://www.intercell. com/main/forvaccperts/products/japanese-encephalitis-vaccine/ [Last accessed 26 May 2009]
55. Duggan ST, Plosker GL. Japanese Encephalitis Vaccine (Inactivated, Adsorbed) [IXIARO]. Drugs 2009;69(1):115-122
56. Tauber E, Kollaritsch H, von Sonnenburg F, et al. Randomized, double-blind, placebo-controlled phase3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008;198(4):493-499 • A pivotal safety trial of IXIARO compared with a PBS/Alum placebo.
57. Dubischar-Kastner K, Kaltenboeck A, Schuller E, et al. Six months safety of a vero-cell derived Japanese Encephalitis vaccine, IXIARO, IC51, across phase3 trials and in a long term follow up cohort [abstract 836]. Proceedings of ASTMH Annual Meeting; Dec 7-11, 2008; New Orleans, USA. •• Pooled analysis of safety data across Phase III studies of IC51.
58. Rendi-Wagner P, Kundi M, Zent O, et al. Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3years following the last immunisation. Vaccine 2004;23(4):427-434 (Pubitemid 39463025)
59. Plesner AM. Allergic reactions to Japanese encephalitis vaccine. Immunol Allergy Clin North Am 2003;23(4):665-697 •• A comprehensive review of neurological and allergic reactions to Japanese encephalitis vaccines.
60. Ohtaki E, Matsuishi T, Hirano Y, Maekawa K. Acute disseminated encephalomyelitis after treatment with Japanese B encephalitis vaccine (Nakayama-Yoken and Beijing strains). J Neurol Neurosurg Psychiatry 1995;59(3):316-317
61. Nazareth B, Levin J, Johnson H, Begg N. Systemic allergic reactions to Japanese encephalitis vaccines. Vaccine 1994;12(7):666 (Pubitemid 24153536)
62. Andersen MM, Ronne T. Side-effects with Japanese encephalitis vaccine. Lancet 1991;337(8748):1044
63. Presseportal 2006. Available from: http://www.presseportal.de [Last accessed 16 April 2009]
64. Shlim DR, Solomon T. Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clin Infect Dis 2002;35(2):183-188 (Pubitemid 34753904)
65. Steffen R, Connor BA. Vaccines in travel health: from risk assessment to priorities. J Travel Med 2005;12(1):26-35 (Pubitemid 40216108)
66. Wittesjo B, Eitrem R, Niklasson B, et al. Japanese encephalitis after a 10-day holiday in Bali. Lancet 1995;345(8953):856-857
67. Lehtinen VA, Huhtamo E, Siikamaki H, Vapalahti O. Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand. J Clin Virol 2008;43(1):93-95
68. Caramello P, Canta F, Balbiano R, et al. A case of imported JE acquired during short travel in Vietnam. Are current recommendations about vaccination broader? J Travel Med 2007;14(5):346-348
69. Berg SW, Mitchell BS, Hanson RK, et al. Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine. Clin Infect Dis 1997;24(2):265-266
70. Jong EC, Tsai TF. Reassessing the risk of Japanese Encephalitis in travelers: lessons from case reports. Proceedings of ASTMH Annual Meeting; Dec 7-11, 2008; New Orleans, USA: Amended abstract 2945